Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

Recently, assays were developed for kidney-specific urinary clusterin (uClus) and serum and urine cystatin B (sCysB, uCysB, respectively). To assess their utility, 40 dogs were recruited and categorized to healthy controls, chronic kidney disease (CKD), AKI and UTI. Median uClus/uCr was 40 ng/mg (range 3-157), 43 (12-6189), 1740 (391-11,834) and 6964 (102-69,855) in control, UTI, CKD and AKI groups, respectively. It differentiated control and AKI (receiver operating [ROC] area under curve [AUC] 0.96, 95% CI: 0.88-1.00). ROC analysis applied to all dogs, had an AUC of 0.86, (95% CI: 0.72-0.97). A cut-off of 3380 ng/mg resulted in 80% sensitivity and 90% specificity. Median sCysB was 206 ng/ mL (range 113-291), 608 ng/mL (200-1348) and 1763 ng/mL (604-4175), in control, CKD and AKI groups, respectively. It differentiated control and AKI (AUC 1.0, 95% CI: 1.00-1.00). ROC analysis applied to all dogs showed AUC of 0.91 (95% CI: 0.79-1.00). A 700 ng/mL cut-off, gave 88% sensitivity and 86% specificity. ROC analysis of uCysB comparing AKI to all other groups gave an AUC of 0.87 (95% CI: 0.74-1.00). A 485 ng/mL cut-off was associated with sensitivity and specificity of 79% and 83%, respectively.